1 Min Read
Oct 25 (Reuters) - Prometic Life Sciences Inc-
* Prometic receives fast track designation for PBI-4050 in development for idiopathic pulmonary fibrosis (IPF) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.